Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study-Reference-Cited by-同舟云学术

Antibody–drug conjugate, GSK2857916, in relapsed/refractory multiple myeloma: an update on safety and efficacy from dose expansion phase I study

Published:2019-03-20 Issue:4 Volume:9 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Trudel Suzanne,Lendvai Nikoletta,Popat Rakesh,Voorhees Peter M.,Reeves Brandi,Libby Edward N.,Richardson Paul G.,Hoos Axel,Gupta Ira,Bragulat Veronique,He Zangdong,Opalinska Joanna B.,Cohen Adam D.

Funder

GlaxoSmithKline

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology

Link

http://www.nature.com/articles/s41408-019-0196-6.pdf

Reference26 articles.

1. Fairfield, H., Falank, C., Avery, L. & Reagan, M. R. Multiple myeloma in the marrow: pathogenesis and treatments. Ann. NY Acad. Sci. 1364, 32–51 (2016).

2. Kumar, S. K. et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia 31, 2443–2448 (2017).

3. O’Connor, B. P. et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199, 91–98 (2004).

4. Lee, L. et al. Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma. Br. J. Haematol. 174, 911–922 (2016).

5. Sanchez, E. et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br. J. Haematol. 158, 727–738 (2012).

Cited by 180 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decoding the Mystery of Blood Cancer: Cause, Diagnosis, and Management;Current Cancer Therapy Reviews;2025-01

2. Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial;Blood Cancer Journal;2024-09-11

3. Corneal Toxicity in Patients Treated by BELANTAMAB MAFODOTIN: How to Improve and Facilitate Patients Follow-Up Using Refractive Shift?;Journal of Ocular Pharmacology and Therapeutics;2024-07-08

4. Belantamab mafodotin concentration–QTc relationships in patients with relapsed or refractory multiple myeloma from the DREAMM‐1 and ‐2 studies;British Journal of Clinical Pharmacology;2024-06-23

5. Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real‐world setting: The ALFA study;European Journal of Haematology;2024-05-09